Global Hyoscine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hyoscine Market Research Report 2024
Hyoscine, also referred as scopolamine, is utilized as a medicine to treat motion sickness, gastrointestinal spasms, vomiting, and postoperative nausea. In addition, it is utilized sometimes before surgery to decrease saliva. Hyoscine belongs to antimuscarinic family and works by blocking some acetylcholine effects within the nervous system.
According to Mr Accuracy reports new survey, global Hyoscine market is projected to reach US$ 617.1 million in 2029, increasing from US$ 442.6 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyoscine market research.
The increased incidence of motion sicknesses such as nausea and vomiting further led to the adoption of hyoscine medicines. Additionally, the market's growth is aided by increased research in the field of Hyoscine. For instance, an article published on April 2022 by BMC Journal showed that pre-treatment with intravenous hyoscine butyl-bromide (HBB) is a risk-free method for both the mother and the child in cesarean section patients undergoing spinal anesthesia to lower the risk of severe intraoperative bradycardia. Furthermore, the increase in travel worldwide is likely to boost the hyoscine market since motion sickness is mainly treated with hyoscine. For instance, as per the June 2022 report from UNWTO, the latest World Tourism Barometer showed an increase of 182% for international tourism in the first three months of 2022 compared to the previous year.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hyoscine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Alchem International Ltd.
Alkaloids Corporation
Baxter International Inc.
Caleb Pharmaceuticals, Inc.
Centroflora Cms S. R.L.
GlaxoSmithKline Plc
Guangzhou Hanfang Pharmaceutical Co., Ltd.
Myungmoon Pharma Co., Ltd.
Novartis International AG
Perrigo Company Plc
Boehringer-Ingelheim
Linnea
C2 PHARMA
Segment by Type
Hyoscine Butylbromide
Hyoscine Hydrobromide
Oral
Injections
Patches
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Hyoscine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Hyoscine market is projected to reach US$ 617.1 million in 2029, increasing from US$ 442.6 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyoscine market research.
The increased incidence of motion sicknesses such as nausea and vomiting further led to the adoption of hyoscine medicines. Additionally, the market's growth is aided by increased research in the field of Hyoscine. For instance, an article published on April 2022 by BMC Journal showed that pre-treatment with intravenous hyoscine butyl-bromide (HBB) is a risk-free method for both the mother and the child in cesarean section patients undergoing spinal anesthesia to lower the risk of severe intraoperative bradycardia. Furthermore, the increase in travel worldwide is likely to boost the hyoscine market since motion sickness is mainly treated with hyoscine. For instance, as per the June 2022 report from UNWTO, the latest World Tourism Barometer showed an increase of 182% for international tourism in the first three months of 2022 compared to the previous year.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hyoscine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alchem International Ltd.
Alkaloids Corporation
Baxter International Inc.
Caleb Pharmaceuticals, Inc.
Centroflora Cms S. R.L.
GlaxoSmithKline Plc
Guangzhou Hanfang Pharmaceutical Co., Ltd.
Myungmoon Pharma Co., Ltd.
Novartis International AG
Perrigo Company Plc
Boehringer-Ingelheim
Linnea
C2 PHARMA
Segment by Type
Hyoscine Butylbromide
Hyoscine Hydrobromide
Segment by Application
Oral
Injections
Patches
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Hyoscine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source